{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:32:32Z","timestamp":1790127152215,"version":"4.0.1"},"reference-count":38,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"TARGET PharmaSolutions, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>As new topical and systemic treatments become available for atopic dermatitis (AD), there is a need to understand how treatments are being used in routine clinical practice, their comparative effectiveness and their long-term safety in diverse clinical settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The TARGET-DERM AD cohort is a longitudinal, observational study of patients with AD of all ages, designed to provide practical information on long-term effectiveness and safety unobtainable in traditional registration trials. Patients with physician-diagnosed AD receiving prescription treatment (topical or systemic) will be enrolled at academic and community clinical centres. Up to 3\u2009years of retrospective medical records, 5\u2009years of prospective medical records, and optional biological samples and patient-reported outcomes will be collected. The primary aims include characterisation of AD treatment regimens, evaluation of response to therapy, and description of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>TARGET-DERM has been approved by a central IRB (Copernicus Group IRB, 5000 Centregreen Way Suite 200, Cary, North Carolina 27513) as well as local and institutional IRBs. No additional Ethics Committee reviews. Results will be reviewed by a publications committee and submitted to peer-reviewed journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03661866\">NCT03661866<\/jats:ext-link>, pre-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-039928","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T20:40:51Z","timestamp":1606509651000},"page":"e039928","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03661866","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-6946","authenticated-orcid":false,"given":"Katrina","family":"Abuabara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-7087","authenticated-orcid":false,"given":"Eric L","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-6430","authenticated-orcid":false,"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-9433","authenticated-orcid":false,"given":"Laura","family":"Dalfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-8558","authenticated-orcid":false,"given":"Julie M","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"D","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"2020112712401758000_10.11.e039928.1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin JM","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"2020112712401758000_10.11.e039928.2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis Is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2020112712401758000_10.11.e039928.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2020112712401758000_10.11.e039928.4","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"2020112712401758000_10.11.e039928.5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaad.2016.05.043","article-title":"Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review","volume":"75","author":"Barbarot","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2020112712401758000_10.11.e039928.6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2020112712401758000_10.11.e039928.7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamadermatol.2016.4129","article-title":"Diversity in dermatology clinical trials: a systematic review","volume":"153","author":"Charrow","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2020112712401758000_10.11.e039928.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"2020112712401758000_10.11.e039928.9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2020112712401758000_10.11.e039928.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023061"},{"key":"2020112712401758000_10.11.e039928.11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2017.07.025","article-title":"Public-Private partnership: targeting real-world data for hepatitis C direct-acting antivirals","volume":"153","author":"Mishra","year":"2017","journal-title":"Gastroenterology"},{"key":"2020112712401758000_10.11.e039928.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08530.x"},{"key":"2020112712401758000_10.11.e039928.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"2020112712401758000_10.11.e039928.14","unstructured":"Eli Lilly and company . Validated investigator global assessment. used with the permission of Eli Lilly and company under a creative commons Attribution-NoDerivatives 4.0 international license, 2017."},{"key":"2020112712401758000_10.11.e039928.15","unstructured":"Harmonising outcome measures for eczema. Available: www.homeforeczema.org"},{"key":"2020112712401758000_10.11.e039928.16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.jid.2017.05.014","article-title":"The International TREatment of ATopic Eczema (TREAT) registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries","volume":"137","author":"Spuls","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2020112712401758000_10.11.e039928.17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J Pharmacol Pharmacother"},{"key":"2020112712401758000_10.11.e039928.18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"2020112712401758000_10.11.e039928.19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2020112712401758000_10.11.e039928.20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamadermatol.2014.4305","article-title":"Association between malignancy and topical use of pimecrolimus","volume":"151","author":"Margolis","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2020112712401758000_10.11.e039928.21","unstructured":"National Jewish Health . Atopic dermatitis research network (ADRN). Available: https:\/\/www.nationaljewish.org\/research-science\/clinical-and-translational-research\/adrn\/overview"},{"key":"2020112712401758000_10.11.e039928.22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/bjd.18452","article-title":"Treatment of atopic eczema (treat) registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema","volume":"182","author":"Bosma","year":"2020","journal-title":"Br J Dermatol"},{"key":"2020112712401758000_10.11.e039928.23","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2020112712401758000_10.11.e039928.24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jdv.13634","article-title":"Psoriasis registries worldwide: systematic overview on registry publications","volume":"30","author":"Eissing","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020112712401758000_10.11.e039928.25","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2016.03.020","article-title":"Review of patient registries in dermatology","volume":"75","author":"DiMarco","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2020112712401758000_10.11.e039928.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08532.x"},{"key":"2020112712401758000_10.11.e039928.27","doi-asserted-by":"publisher","DOI":"10.1111\/all.12942"},{"key":"2020112712401758000_10.11.e039928.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"2020112712401758000_10.11.e039928.29","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15179"},{"key":"2020112712401758000_10.11.e039928.30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jid.2019.08.452","article-title":"Development, validation, and interpretation of the PROMIS itch questionnaire: a patient-reported outcome measure for the quality of life impact of itch","volume":"140","author":"Silverberg","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2020112712401758000_10.11.e039928.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.07.005"},{"key":"2020112712401758000_10.11.e039928.32","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-64"},{"key":"2020112712401758000_10.11.e039928.33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-54"},{"key":"2020112712401758000_10.11.e039928.34","unstructured":"Health measures. Available: http:\/\/www.healthmeasures.net\/index.php"},{"key":"2020112712401758000_10.11.e039928.35","first-page":"997","article-title":"The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"2020112712401758000_10.11.e039928.36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bjd.18657","article-title":"Validation of five patient-reported outcomes for atopic dermatitis severity in adults","volume":"182","author":"Silverberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"2020112712401758000_10.11.e039928.37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","article-title":"Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe","volume":"66","author":"Stalder","year":"2011","journal-title":"Allergy"},{"key":"2020112712401758000_10.11.e039928.38","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-039928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:11:44Z","timestamp":1697256704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-039928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-039928"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-039928","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}